- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02049047
Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy (ONC-2010-001)
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Given the high expression of IGF-1R and pAKT proteins in thymoma tissues, able to sensitize tumors to mTOR inhibition, and the anticancer activity of the mTOR inhibitors, clinical evaluation in thymoma and thymic carcinoma seems to be very interesting.
Patients will receive continuous treatment with oral everolimus 10 mg once daily.
Efficacy and safety profile of Everolimus will be evaluated.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
MI
-
Rozzano, MI, Italy, 20089
- Istituto Clinico Humanitas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological diagnosis of invasive recurrent or metastatic thymoma or thymic carcinoma confirmed by pathologist.
- At least one prior platinum-containing chemotherapy regimen. There is no limit to the number of prior chemotherapy regimens received. Progressive disease should have been documented before entry into the study.
- Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as greater than 20 mm with conventional techniques or as greater than 10 mm with spiral CT scan.
- Patients must have recovered from toxicity related to prior therapy to at least to grade 1 (defined by CTCAE 3.0).
- No major surgery, radiation therapy, chemotherapy, biologic therapy (including any investigational agents), or hormonal therapy (other than replacement), within 4 weeks prior to entering the study.
- Life expectancy of at least 3 months.
- Performance status (ECOG)<=2
- Negative pregnancy test (if female in reproductive years)
- Adequate organ and marrow function (as defined below)
- Leukocytes >=3,000/mm, Absolute neutrophil count >=1,500/mm, Hemoglobin>= 9 g/dL, Platelets>= 100,000/mm, Total bilirubin >= 1.5 x institutional upper limit of normal (ULN), AST(SGOT)/ALT(SGPT)>= 3 x institutional ULN (5x if LFT elevations due to liver metastases, )Creatinine <= 1.5 x institutional ULN
Exclusion Criteria:
- Patients with symptomatic brain metastases. However, patients who have had treatment for their brain metastases and whose brain metastatic disease status has remained stable for at least 3 months without steroids may be enrolled at the discretion of the investigator.
- Major surgery, other than diagnostic surgery, within 4 weeks prior to treatment
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
- Pregnant or breast feeding women
- Previous (within the last 5 years) or current malignancies at other sites, except for adequately treated basal cell or squamous cell skin cancer or in situ carcinoma of the cervix uteri
- Current enrollment in or participation in another therapeutic clinical trial within 4 weeks preceding treatment start.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgement of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Everolimus
oral everolimus
|
Everolimus will be orally administered at the dosage of 10 mg once daily.
Each cycle will be considered as 21 days of treatment.
Tumor assessment will be done every two cycles.Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
disease control rate
Time Frame: 6 months
|
disease control rate (DCR), considered as complete response (CR) plus partial response (PR) plus stable disease (SD), of Everolimus monotherapy
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: 6 months
|
Progression free survival (PFS) will be evaluated from the date of treatment start until the date of progression or death whichever occurs first, otherwise until the last visit date.
|
6 months
|
Duration of Response
Time Frame: 6 months
|
This endpoint is assessed in patients whose best tumor response is CR or PR as the time from the date of the first documentation of confirmed objective tumor response to the date of first documentation of objective tumor progression, objective tumor recurrence, or of death due progressive disease, whichever comes first
|
6 months
|
OS
Time Frame: 6 months
|
Overall Survival (OS) will be evaluated from the date of treatment start until the date of death or last contact for patients alive at the end of the study.
|
6 months
|
FDG-PET imaging relations
Time Frame: 6 weeks
|
To correlate response to therapy with changes in FDG-PET imaging at baseline and first restaging.
|
6 weeks
|
safety profile
Time Frame: 6 months
|
Overall safety profile, evaluated on the basis of laboratory and clinical safety parameters
|
6 months
|
biomarkers expression
Time Frame: 6 months
|
To perform immunohistochemistry for IGF-1R, pAKT ,mTOR, p-S6K, p-S6, p-4E-BP1, and pTEN expression in all pre-treatment tissue specimens of thymoma and thymic carcinoma and correlate with response and survival (PFS and OS).
|
6 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Lymphatic Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Thoracic Neoplasms
- Neoplasms, Complex and Mixed
- Carcinoma
- Thymoma
- Thymus Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Everolimus
Other Study ID Numbers
- ONC-2010-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thymoma and Thymic Carcinoma
-
National Cancer Institute (NCI)TerminatedInvasive Thymoma and Thymic Carcinoma | Recurrent Thymoma and Thymic Carcinoma | Stage III Thymoma | Stage IVA Thymoma | Stage IVB ThymomaUnited States
-
Erasmus Medical CenterHospices Civils de Lyon; Maastro Clinic, The NetherlandsRecruitingThymic Carcinoma | Thymoma | Thymic Epithelial Tumor | Thymoma and Thymic CarcinomaNetherlands
-
Fudan UniversityRecruitingThymoma and Thymic CarcinomaChina
-
MedSIRMerck Sharp & Dohme LLCActive, not recruitingMetastatic Thymic Carcinoma | Thymoma Type B3Spain, France, Italy
-
Jian ChenRecruitingCarbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, ChemotherapyChina
-
Fudan UniversityCompletedThymoma and Thymic CarcinomaChina
-
Sun Yat-sen UniversityActive, not recruitingThymoma and Thymic CarcinomaChina
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingUnresectable Thymic Carcinoma | Metastatic Thymic Carcinoma | Locally Advanced Thymic Carcinoma | Recurrent Thymic CarcinomaUnited States
-
Tang-Du HospitalRecruitingThymoma and Thymic CarcinomaChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Thymoma AJCC v8 | Stage IIIA Thymoma AJCC v8 | Stage IIIB Thymoma AJCC v8 | Stage IV Thymoma AJCC v8 | Stage IVA Thymoma AJCC v8 | Stage IVB Thymoma AJCC v8 | Unresectable Thymic CarcinomaUnited States
Clinical Trials on Everolimus
-
Novartis PharmaceuticalsTerminatedHepatocellular CarcinomaHong Kong, Taiwan, Thailand
-
German Breast GroupNovartisTerminatedMetastatic Breast CancerGermany
-
The Netherlands Cancer InstituteActive, not recruitingNeuroendocrine CarcinomasNetherlands
-
Novartis PharmaceuticalsCompletedLymphangioleiomyomatosis (LAM) | Tuberous Sclerosis Complex (TSC)United States, United Kingdom, Germany, Italy, Russian Federation, Netherlands, Japan, Canada, Poland, France, Spain
-
University of LuebeckTerminatedCoronary Artery DiseaseGermany
-
Guangdong Provincial People's HospitalNovartisUnknownNeuroendocrine Tumors | Carcinoid TumorChina
-
Novartis PharmaceuticalsCompletedGastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic SystemGermany
-
Novartis PharmaceuticalsTerminatedCarcinoma, Renal CellAustralia, Korea, Republic of
-
Centre Leon BerardSuspended
-
Leiden University Medical CenterUnknownHead and Neck CancerNetherlands